Prostate cancer is the most common cancer among American men, with 217,730 estimated new cases and 32,050 deaths expected in 2010 (1). It can be inferred from these statistics that there is extensive variation in the aggressiveness of prostate cancer, which ranges from completely indolent to highly aggressive. Prostate-specific antigen (PSA) screening has led to a marked increase in the number of patients diagnosed with prostate cancer; most are diagnosed with low-grade disease, but many men are diagnosed with advanced disease. Hence, a rising PSA, although it most likely indicates a low-risk tumor, may also be a harbinger of a deadly malignancy. Many men undergo one or more “blind” prostatic biopsies in response to rising PSA values, but it is possible to miss a large tumor if it is outside the usual biopsy template. Thus, a major role of imaging is to help guide biopsies to detect significant lesions that would otherwise be left undetected.

Unfortunately, predicting the natural history of a particular tumor is difficult, except in extreme situations. Decisions regarding treatments, which include active surveillance (AS), surgery, radiation, and hormonal therapies, are based on the condition and age of the patient as well as the presumed stage of the disease. Imaging plays an important role in staging localized prostate cancer. Magnetic resonance imaging (MRI) best depicts the zonal anatomy, with a superior soft tissue resolution providing better results for tumor localization, monitoring, and local staging. Previously, the major function of prostate MRI has been in staging, and this role remains important. In this article, we introduce the reader to the expanding roles that MRI plays in the management of localized prostate cancer.

Key words: • prostate cancer • magnetic resonance imaging • prostate specific antigen

From the Molecular Imaging Program (B.T. baris@turkbey@yahoo.com, P.L.C.), the Laboratory of Pathology (M.J.M.), and the Urologic Oncology Branch (P.A.P.), National Cancer Institute, NIH, Bethesda, MD, USA; SAIC-Frederick (M.B.), NCI, Frederick, MD, USA; the Center for Interventional Oncology (B.J.W.), NCI; and Radiology and Imaging Sciences, Clinical Center, NIH, Bethesda, MD, USA.

Received 15 April 2011; revision requested 27 May 2011; revision received 31 May 2011; accepted 6 June 2011.

Published online 16 September 2011
DOI 10.4261/1305-3825.DIR.4478-11.1

MRI of the prostate: normal anatomy and prostate cancer

The basic prostate MRI begins with the placement of an endorectal coil (ERC) following a digital rectal examination (DRE) and involves the acquisition of T2-weighted (T2W) images, diffusion-weighted images, MR spectroscopy, and dynamic contrast-enhanced (DCE) MRI. Imaging can be performed without an endorectal coil, but the quality is usually markedly reduced, especially in diffusion-weighted (DW) imaging and DCE-MRI. Poor image quality makes MRI much more difficult to interpret. Despite the gain in signal from an ERC, its use is perceived as invasive by patients and radiologists. Although an ERC is still considered mandatory for many patients, new phased array coil designs and pulse
sequences are alternatives that yield comparable image quality.

Anatomically, the prostate can be divided into the peripheral zone and central gland (including the transitional and central-periurethral zones). The normal PZ appears high in signal on T2W MRI, whereas a normal CG has a lower and more heterogeneous signal intensity. The CG is separated from the PZ by a pseudocapsule or surgical capsule. The true capsule, a hypointense rim surrounding the PZ, defines the limits of the prostate and is the site of extracapsular extension. The neurovascular bundles, critical for erectile function, are located at approximately 5 and 7 o’clock posterolateral to the true capsule. The seminal vesicles appear as hyperintense thin-walled cystic structures on T2W MRI, whereas the more medial paired vas deferens are thick-walled and hypointense and can mimic seminal vesicle invasion (Fig. 1). Lymph nodes draining the prostate can be found in the obturator fossa and the peri-rectal space, and higher in the midline of the retroperitoneum.

Prostate cancers usually arise in the PZ and appear as round or ill-defined low-signal-intensity foci on T2W MR images. Detecting tumors in the CG is more complex because the CG becomes progressively larger and more heterogeneous with age; CG tumors are defined as homogenous, low-signal-intensity lesions with irregular margins and without a capsule. They often invade the pseudocapsule or appear lenticular with extensions into the urethra or anterior fibromuscular zone (2, 3). On DW-MRI, prostate cancers are high in signal due to reduced diffusion, whereas on apparent diffusion coefficient (ADC) maps, they are low in signal intensity (2). On MR spectroscopy, elevated choline levels and/or an elevated ratio of choline to citrate are indicators of prostate cancer (4). On DCE-MRI, prostate cancer usually shows early, rapid enhancement and early washout (5).

Clinical roles of prostate MRI

MRI for local staging after a “positive” TRUS-guided biopsy

As an example, we will follow the typical course of a patient with a rising PSA but no definable lesion on their DRE. Such patients undergo 6–24 systematic core biopsies under transrectal ultrasound guidance (Fig. 2). Patients with an abnormal DRE and/or rising serum PSA usually undergo transrectal ultrasonography (TRUS) guided prostate biopsy, the accepted “gold standard” for diagnosis. The main limitation of the TRUS-guided biopsy is that only a small percentage of the gland is sampled. The lateral PZ may be oversampled, while the midline, antero-lateral, and anterior aspects of the prostate and the CG may be undersampled. The size, location, and extent of the tumor can influence decision making and are generally unknown on the basis of the biopsy alone. Therefore, such patients can be evaluated with an ERC MRI to determine the size of the tumor. The size or location of the lesion seen on MRI can trigger an additional guided biopsy. For instance, if the initial biopsy suggests a “minimal cancer”, but the MRI identifies a large mass, the patient may then be re-biopsied to obtain a more representative sample (Fig. 3). Prostate cancer is a multifocal, and biologically and histologically heterogeneous disease, which can easily lead to sampling errors (6). Staging by MRI involves visualizing the size and location of the tumor, and the status of the prostate capsule (Fig. 4), seminal vesicles, bladder wall, and local lymph nodes (Fig. 5) (7–21). It should be noted, however, that MRI generally underestimates nodal involvement because it relies on nodal enlargement. The use of MRI for local staging after a “positive” TRUS-guided biopsy constitutes approximately 48% of the total referrals at our center.

MRI for screening before a TRUS-guided biopsy

A recent debate on the clinical application of prostate MRI centers on whether it can be used as a screening tool before systematic prostate biopsies in patients with an elevated PSA and an abnormal DRE (Fig. 2). Shimizu et al. (22) have recently reported that MRI before a biopsy resulted in a higher rate of prostate cancer detection in 122 patients who underwent T2W MRI and DW-MRI with only a 4-channel external phased array coil. The investigators argue that the use
Figure 2. Flowchart demonstrating the use of prostate MRI in several clinical scenarios. Route 1 (red) represents the current most common clinical use of MRI as a local staging tool after a positive biopsy and before treatment. Route 2 (purple) represents its use as a “screening tool” before biopsy. Route 3 (green) depicts its role as a “monitoring tool” in active surveillance. Route 4 (blue) represents its use as a “guidance tool” for patients with previous negative biopsies but rising serum PSA. Percentages denote the referral rate of each route on a per patient basis. PSA, prostate-specific antigen; DRE, digital rectal examination.

Figure 3. a–d. Images from a 59-year-old patient with serum PSA of 8.71 ng/dL and a Gleason-score 3+3 (15% of core) tumor at the right base PZ detected by TRUS-guided biopsy prior to MRI. The axial T2W MR image (a) shows a hypointense lesion in the right mid-base peripheral zone (red asterisk); an ADC map of DW-MRI (b) shows restricted diffusion as a hypointense focus (red asterisk); MR spectroscopy (c) demonstrates an increased choline/citrate ratio within the lesion (white asterisks); and a quantitative map (d) obtained from DCE-MRI localizes the tumor (arrow). The patient underwent a TRUS-MRI-fusion-guided biopsy after MRI, and the right mid-base peripheral zone lesion was found to be upstaged to a Gleason-score 4+4 (90% of core) prostate cancer.
Figure 4. a–e. Images from a 57-year-old patient with a PSA of 3.35 ng/dL and a Gleason-score 3+4 (70% of core) tumor at the right apical peripheral zone, detected by a TRUS-guided biopsy prior to MRI. The axial T2W MR image (a) shows a hypointense lesion in the right apical peripheral zone with extracapsular extension (arrow); an ADC map of DW-MRI (b) shows restricted diffusion as a hypointense focus (arrow) corresponding to the right apical peripheral zone lesion; MR spectroscopy (c) demonstrates an increased choline/citrate ratio within the lesion (white asterisk); and a raw DCE-MR image (d) and quantitative map (e) obtained from DCE-MRI localize the tumor (arrows in d and e).
Figure 5. a–e. Images from a 43-year-old patient with a PSA of 30 ng/dL. The axial T2W MR image (a) shows a hypointense lesion in the left apical peripheral zone (red asterisk); an ADC map of DW-MRI (b) shows restricted diffusion as a hypointense focus (red asterisk) corresponding to the left apical peripheral zone lesion; the raw DCE-MR image (c) and the quantitative map (d) obtained from DCE-MRI localize the tumor (red asterisk in c, arrow in d); and an axial contrast-enhanced T1W image of the pelvis (e) shows an enlarged left iliac lymph node secondary to prostate cancer metastases (black asterisks).
of MRI data during biopsies (e.g., TRUS-MRI fusion for guidance) can potentially decrease the number of patients undergoing unnecessary prostate biopsies and increase the yield of those who do, but the cost-effectiveness of this approach has not been demonstrated (23) (Fig. 6). Some patients, recognizing the “blind” nature of routine biopsies, request ERC MRIs before their first biopsy. Referrals to MRI for pre-biopsy screening constitute approximately 17% of total referrals in our practice.

MRI as a roadmap after one or more “negative” TRUS-guided biopsies

Patients with negative biopsies return to the screening pool (Fig. 2). If their PSA levels continue to rise after a negative biopsy, the next step in patient management becomes challenging, especially considering that up to 90% of patients have a negative result after an initial negative biopsy (24, 25). One option for such cases is the saturation biopsy, which may include obtaining 100 or more cores; however, this procedure can result in complications such as urinary retention, hematuria and sepsis, and is costly due to multiple specimen processing and interpretation (26). Another approach is to use MRI to localize suspicious areas for biopsy, especially if the lesion is in the anterior and CG lesions, the site of approximately 20%–30% of all prostate cancers (27, 28). An MRI scan at this point may direct the biopsy to an area that would not ordinarily be sampled (Fig. 7). Recently, MRI in patients with persistently elevated PSA and one or more prior negative prostate biopsies was reported to increase tumor detection rate by 25%–45% on a per-patient basis (29–32). In addition to using MR images as a virtual guide for repeat biopsies, the biopsy procedure can be performed under real-time MRI guidance or potentially combined with real-time TRUS to guide repeat biopsies (33, 34). MRI has been used as a problem-solving tool following “negative” and “inconclusive” biopsies in 17% of our prostate MRI referrals.

Figure 6. a–d. Images from a 50-year-old patient with a serum PSA of 15.8 ng/dL without any prior prostate biopsy history. The axial T2W MR image (a) shows a hypointense lesion in the right mid-base anterior central gland (red asterisk); an ADC map of DW-MRI (b) shows restricted diffusion within the lesion (red asterisk); and a raw DCE-MR image (c) and the quantitative map (d) obtained from DCE-MRI demonstrate early and fast enhancement within the lesion (red asterisks). The patient underwent TRUS-MRI-fusion-guided prostate biopsy, and the right mid-base anterior central gland lesion was found to contain Gleason-score 4+5 (100% of core) prostate cancer.
Figure 7. a–e. Images from a 67-year-old patient with a serum PSA of 21.4 ng/dL with seven negative TRUS-guided prostate biopsies prior to MRI. The axial T2W MR image (a) shows a hypointense lesion in the mid-anterior central gland (arrow and red asterisk); an ADC map of DW-MRI (b) shows restricted diffusion within the lesion (red asterisk); MR spectroscopy (c) demonstrates an increased choline/citrate ratio within the lesion (white asterisks); and a raw DCE-MR image (d) and the quantitative map (e) obtained from DCE-MRI demonstrate early and fast enhancement within the lesion (red asterisk). The patient underwent TRUS-MRI-fusion-guided prostate biopsy, and the mid-anterior central gland lesion was found to contain Gleason-score 3+4 (70% of core) prostate cancer.
MRI as a monitoring tool for active surveillance

Because prostate cancer exists as a spectrum of pathologies that range from indolent to highly aggressive, and patients with indolent cancers may not require radical prostatectomy or radiation therapy, AS is often suggested for patients with low-volume and clinically low-risk disease (35–38). Multiparametric MRI, including T2W MRI, DW-MRI, MR spectroscopy, and DCE-MRI, can potentially help to correctly stratify such patients in the pretreatment phase because it may help predict patterns of tumor growth and thus identify the prognosis (39–46).

Studies have suggested that AS may be an alternative to radical therapies for carefully selected patients (47, 48). AS is an emerging methodology that involves serial PSA measurements and annual biopsies, and it has not been standardized (49, 50). A few large-scale clinical studies have recently reported favorable outcomes using AS of prostate cancer (51, 52). Lesions eligible for AS can be depicted by multiparametric MRI and tracked, allowing tumors that transform to a more aggressive phenotype to be identified (53, 54) (Figs. 8 and 9). The AS patient...
population constitutes 13.5% of prostate MRI referrals in our practice.

**MRI as a monitoring tool for treatment follow-up**

The treatment options for patients with prostate cancer include radical prostatectomy (RP), hormone therapy, radiation therapy (e.g., external beam radiation and brachytherapy) and focal therapy (radiofrequency ablation, cryotherapy, high-intensity focus ultrasound, and cyberknife). Selection of the optimal treatment method is based on clinical tumor stage, Gleason score, PSA level, and other factors such as patient age, condition and other comorbidities. Patients are followed by serum PSA and DRE after treatment for prostate cancer. MRI can play a role in detecting local recurrence when PSA begins to rise after anadir. For instance, biochemical relapse after RP can occur in 15%–30% of patients (55–58). Currently, clinical nomograms are used to predict the risk of biochemical recurrence; however, these nomograms have some limitations related to their variables, such as the low specificity of serum PSA and underestimated Gleason score at biopsy. MRI has been shown to improve the detection of local recurrence in patients with RP in
a few studies (59–60). Although it is challenging to detect local recurrence on T2W MR images, the combined use of T2W MRI with DCE-MRI results in a higher yield in detecting local recurrence (61) (Fig. 10).

External-beam radiation therapy (EBRT) is employed in approximately one-third of prostate cancer patients, and biochemical recurrence can occur in 20%–40% in the first five years (62). Detecting recurrence after EBRT can be challenging because the PSA level may not be a reliable marker, and the DRE can be non-specific due to atrophic and fibrotic changes in the irradiated prostate gland. Multi-parametric MRI, specifically MR spectroscopy and DCE-MRI, can help identify recurrences with high accuracy in post-radiotherapy patients (63–66). Post-treatment follow-up comprises 4.5% of prostate MRI referrals. Similar comments apply to focal therapies such as focal cryotherapy and high-intensity focused ultrasound (Fig. 11).

Among the available imaging modalities, MRI currently provides the most valuable anatomic and functional information about the prostate gland. Although MRI yielded disappointing results when used in staging, its role has expanded with changes in how prostate cancer is perceived, treated and followed. MRI is currently mostly used for localization and local staging in prostate cancer patients who are surgery or radiation candidates. However, in addition to its traditional roles, MRI is being used as a monitoring tool in AS and in RP and post-radiation patients; it is also used to help diagnose patients with negative prior biopsies but rising PSA (Fig. 2). Prostate MRI has come of age in the PSA era.

**Conflict of interest disclosure**

The authors declared no conflicts of interest.

**References**


